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ABSTRACT
The role of Candida in antibiotic-associated diarrhoea (AAD) has been controversial for many years.
Since Candida exists physiologically in the gastrointestinal tract, the presence of small numbers of
Candida organisms in stool has therefore been considered normal, and thus non-pathogenic. Increased
Candida counts have been linked to the development of diarrhoea in antibiotic-treated patients.
However, recent ﬁndings have not conﬁrmed this. To date, there is no convincing evidence that Candida
may cause AAD in adults.
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The role of Candida spp. in antibiotic-associated
diarrhoea (AAD) has been controversial for many
years. Reported cases of AAD associated with
Candida that responded to antifungal treatment,
and the presence of high faecal counts of Candida
(‡ 105 CFU ⁄mL stool) in patients with AAD,
supported this association. However, the publi-
cation of a few anecdotal case reports of suspected
Candida-associated AAD failed to establish con-
vincingly that Candidamay be a causative agent of
AAD [1–4], and several recent studies have
attempted to elucidate the relationship between
Candida spp. and AAD in more detail.
A study involving 395 patients, with or without
diarrhoea, and independent of antibiotic treat-
ment, investigated the presence and numbers of
Candida spp. in stool. It was shown that the rates
of isolation of Candida from faeces and Candida
overgrowth in AAD patients did not differ from
those of patients without diarrhoea who were also
taking antibiotics. Candida overgrowth among
patients with diarrhoea who were not taking
antibiotics was less frequent than among AAD
patients, but the frequency of Candida isolation
was the same. In control subjects without diar-
rhoea who were not taking antibiotics, the fre-
quencies of Candida isolation and overgrowth
were less common than in all the other groups.
Exploratory analysis using different cut-off values
for the deﬁnition of Candida overgrowth (103, 104,
105, 106 or 107 CFU ⁄mL stool) yielded qualita-
tively similar results: in all calculations, Candida
overgrowth was signiﬁcantly less common in the
control group than in all the other groups [5]. It
was suggested that the decrease of bacteria in the
stool, caused by either antibiotic therapy or
dilution in watery stools, resulted in increased
counts of Candida [5].
It has also been hypothesised that a fungal
toxin or toxin-like substances may cause AAD
[1,3,6]. Candida produces two main virulence
factors, namely secreted aspartyl proteinases
(Saps) and phospholipases, and both virulence
factors have been investigated recently to deter-
mine their possible role in AAD. All strains of
Candida albicans obtained from AAD patients
and controls produced Saps, with no signiﬁcant
difference in the amount produced between the
two groups [5]. In addition, the production of
phospholipase by faecal Candida isolates from
patients with AAD did not differ from that of
controls [7]. It can be concluded from these
studies that the major fungal virulence factors,
Saps and phospholipase, are not responsible for
AAD in adults.
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Another study, prompted by the presence of
elevated Candida counts in AAD patients, inves-
tigated the faecal environment and its inﬂuence
on the growth of Candida spp. Physiologically, the
indigenous microﬂora forms a dense layer of
mucus that competes successfully with yeasts for
adhesion sites, and produces inhibitor substances
such as short-chain fatty acids and secondary bile
acids. C. albicans adhesion is reduced and the
growth of Candida is suppressed further by the
competition for growth-limiting nutrients [8–10].
It was shown [11] that the superior growth of
Candida in stool ﬂuid from AAD patients, com-
pared to that from healthy subjects, was caused
by a reduction in soluble growth-inhibiting fac-
tors (e.g., short-chain fatty acids and secondary
bile acids) for Candida, and increased availability
of growth and nutrient factors for the indigenous
microﬂora. The study demonstrated that a normal
intestinal bacterial microﬂora is important in
maintaining a balanced intestinal micro-ecology
with low counts of Candida. It has also been
shown that a reduction, by itself, in the popula-
tion of certain anaerobic bacteria, plus the subse-
quent reduction in the metabolism of undigested
ﬁbre and starch to short-chain fatty acids (in
particular, butyrate), causes AAD [12].
The theory that Candida may cause AAD was
also based on studies concerning antifungal treat-
ment and anecdotal case reports of rapid abate-
ment of gastrointestinal symptoms following
antifungal therapy. However, the design of most
of these studies did not include controls, and the
reports are based on small numbers of investigated
patients. In one study, ﬁve of seven patients with
Candida overgrowth and AAD were treated suc-
cessfully with nystatin [1]. In another study, two of
nine patients with AAD and Candida overgrowth
received nystatin, and their stools solidiﬁedwithin
6 days [4]. Among a further ten patients with
diarrhoea andCandida in their stools, all responded
to nystatin treatment [3]. However, two of these ten
patients did not have AAD, and four patients had
received antibiotic treatment with clindamycin,
which is known to cause soft stools and diarrhoea
in up to 25% of cases [13]. In the remaining
patients, other causes of diarrhoea (e.g., post-
radiation colitis, toxic or pharmacological effects
of antibiotics) were not excluded.
Large trials comparing rates of Candida isola-
tion among antibiotic-treated patients, with and
without diarrhoea, have been undertaken to
clarify the role of Candida in AAD. The resulting
data show that both antibiotic therapy and diar-
rhoea itself are responsible for increased faecal
counts of Candida [5,11], which leads to the
conclusion that the increase is a result of antibiotic
treatment or diarrhoea (leading to disturbance of
the indigenous intestinal microﬂora and short-
chain fatty acids) rather than a cause of AAD. The
fact that the fungal toxins Saps and phospholipase
are not responsible for AAD in adults has been
established [5,7], and there is no convincing
evidence to date that Candida overgrowth can
cause AAD in adults.
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